Abstract: A combining network for an array of SPAD devices includes: synchronous sampling circuits, wherein each synchronous sampling circuit is coupled to an output of a corresponding SPAD device and is configured to generate a pulse or an edge each time an event is detected; and a summation circuit coupled to an output of each of the synchronous sampling circuits and configured to count a number of pulses or edges to generate a binary output value.
Abstract: The invention relates a compound of the formula: a pharmaceutically acceptable salt thereof, compositions thereof, and methods of therapeutic treatment using the same.
Type:
Grant
Filed:
June 10, 2020
Date of Patent:
December 22, 2020
Assignee:
GlaxoSmithKline Intellectual Property Development Limited
Inventors:
Richard M Dunham, David Margolis, Vincent Wing-Fai Tai, Jun Tang
Abstract: A ranging system includes a first ranging unit with a first laser driver, a first control circuit generating a first trigger signal, and a first data interface with a first trigger transmitter transmitting the first trigger signal over a first data transmission line and a first calibration receiver receiving a first calibration signal over a second data transmission line. A second ranging unit includes a second laser driver, a second data interface with a second trigger receiver receiving the first trigger signal and a second calibration transmitter transmitting the first calibration signal, and a second control circuit generating the first calibration signal in response to receipt of the first trigger signal. The first control circuit determines an elapsed time between transmission of the first trigger signal and receipt of the first calibration signal. The determined elapsed time is used to synchronize activation of the first and second laser drivers.
Abstract: An electronic device includes laser emitters, and a laser driver generating a laser drive signal for the laser emitters based upon a feedback control signal. A steering circuit selectively steers the laser drive signal to a different selected one of the plurality of laser emitters and prevents the laser drive signal from being steered to non-selected ones of the plurality of laser emitters, during each of a plurality of time periods. Control circuitry senses a magnitude of a current of the laser drive signal and generates the feedback control signal based thereupon. The feedback control signal is generated so as to cause the laser driver to generate the laser drive signal as having a current with a substantially constant magnitude.
Abstract: The invention relates to an adeno-associated virus (AAV) producer cell comprising nucleic acid sequences encoding: rep/cap gene; helper virus genes; and the DNA genome of the AAV vector particle, wherein the nucleic acid sequences are all integrated together at a single locus within the AAV producer cell genome. The invention also relates to nucleic acid vectors comprising a non-mammalian origin of replication and the ability to hold at least 25 kilobases (kb) of DNA, characterized in that the nucleic acid vectors comprise nucleic acid sequences encoding: rep/cap gene, and helper virus genes. The invention also relates to uses and methods using the nucleic acid vectors in order to produce stable AAV packaging and producer cell lines.
Type:
Grant
Filed:
April 18, 2018
Date of Patent:
December 8, 2020
Assignee:
GlaxoSmithKline Intellectual Property Development Limited
Abstract: The invention is directed to substituted pyrrolidine derivatives. Specifically, the invention is directed to compounds according to Formula III: wherein A, B, L1, L2, L3, R1, R2, R3, R4, R5, R6, R9, R10, R30, Y1, Y2, z2, z4, z5, and z6 are as defined herein, and salts thereof.
Type:
Grant
Filed:
June 7, 2017
Date of Patent:
December 1, 2020
Assignee:
GlaxoSmithKline Intellectual Property Development Limited
Inventors:
Jeffrey Michael Axten, Mui Cheung, Anthony William Dean, Michael P. DeMartino, Hilary Schenck Eidam, Biswajit Kalita, Raghava Reddy Kethiri, Rajendra Kristam
Abstract: A camera module with a fixed near field focus is configured to capture a single image. That single image is segmented by an image divider a number of regions. A focus metric determiner then determines a focus metric for each of the regions. A depth map generator maps the focus metric into a depth value for each of the regions and combines the depth values to generate a depth map.
Abstract: Provided are electric vehicles having a relatively short height (between 1600 mm and 1800 mm), a relatively high ground clearance (at least 260 mm), and a windscreen inclined at a relatively shallow angle (between 25 and 30 degrees relative to the horizontal plane), wherein the horizontal distance between a leading edge of the vehicle and a leading edge of the windscreen is less than 870 mm.
Type:
Application
Filed:
October 29, 2018
Publication date:
November 12, 2020
Applicant:
Dyson Automotive Research and Development Limited
Abstract: A transmit integrated circuit includes a light source configured to generate a beam of light. A receive integrated circuit includes a first photosensor. A transmit optic is mounted over the transmit and receive integrated circuits. The transmit optic is formed by a prismatic light guide and is configured to receive the beam of light. An annular body region of the transmit optic surrounds a central opening which is aligned with the first photosensor. The annular body region includes a first reflective surface defining the central opening and further includes a ring-shaped light output surface surrounding the central opening. Light is output from the ring-shaped light output surface in response to light which propagates within the prismatic light guide in response to the received beam of light and which reflects off the first reflective surface.
Abstract: A wash basin (2) includes a bowl unit (4) and a skirt (6) that supports the bowl unit. The bowl unit (2) is made mainly or entirely of metal and the skirt (6) is made mainly or entirely of a moulded thermoplastic material. The skirt (6) includes a peripheral rim (28) that is located beneath an edge portion (29) of the bowl unit to support that bowl unit, and the bowl unit (4) and the skirt (6) are bonded together.
Abstract: An embodiment method of operating an imaging device including a sensor array including a plurality of pixels, includes: capturing a first low-spatial resolution frame using a subset of the plurality of pixels of the sensor array; generating, using a processor coupled to the sensor array, a first depth map using raw pixel values of the first low-spatial resolution frame; capturing a second low-spatial resolution frame using the subset of the plurality of pixels of the sensor array; generating, using the processor, a second depth map using raw pixel values of the second low-spatial resolution frame; and determining whether an object has moved in a field of view of the imaging device based on a comparison of the first depth map to the second depth map.
Abstract: Disclosed are compounds having the formula: wherein Ra, R1, R2, R3, R4, R5, R6, R7, and R8, are as defined herein, or a salt, particularly a pharmaceutically acceptable salt, thereof.
Type:
Application
Filed:
April 5, 2017
Publication date:
October 15, 2020
Applicant:
GlaxoSmithKline Intellectual Property Development Limited
Inventors:
Adam Kenneth CHARNLEY, Robert Clifford Roback, Robert D. Gilbertson, Hakim Boukhalfa, Scott w. Imbus
Abstract: Methods of treating muscle wasting and other disorders with NOPE extracellular domain (ECD) polypeptides and NOPE ECD fusion molecules are provided.
Type:
Grant
Filed:
April 24, 2017
Date of Patent:
October 13, 2020
Assignees:
Five Prime Therapeutics, Inc., Glaxosmithkline Intellectual Property Development Limited
Inventors:
Aaron Curtis Hinken, Amy W. Hsu, Janine Powers, Warren James Rocque, Alan James Russell
Abstract: The invention is directed to certain novel compounds. Specifically, the invention is directed to compounds of formula (I): and salts thereof. The compounds of the invention are inhibitors of kinase activity, in particular PI3-kinase activity.
Type:
Grant
Filed:
September 17, 2019
Date of Patent:
October 6, 2020
Assignee:
GlaxoSmithKline Intellectual Property Development Limited
Inventors:
Niall Andrew Anderson, Nicholas Paul Barton, Sebastien Andre Campos, Edward Paul Cannons, Anthony William James Cooper, Kenneth David Down, Kevin James Doyle, Julie Nicole Hamblin, Graham George Adam Inglis, Armelle Le Gall, Vipulkumar Kantibhai Patel, Simon Peace, Andrew Sharpe, Gemma Victoria White
Abstract: The invention relates a compound of the formula: a pharmaceutically acceptable salt thereof, compositions thereof, and methods of therapeutic treatment using the same.
Type:
Application
Filed:
June 10, 2020
Publication date:
September 24, 2020
Applicants:
GlaxoSmithKline Intellectual Property Development Limited, The University of North Carolina at Chapel Hill, ViiV Healthcare Company
Inventors:
Richard M DUNHAM, David MARGOLIS, Vincent Wing-Fai TAI, Jun TANG
Abstract: The present invention relates to LpxC antibacterial compounds of Formula (IA): corresponding pharmaceutically acceptable salts thereof, corresponding pharmaceutical compositions, compound preparation, treatment methods and uses for bacterial infections, especially those caused by gram-negative bacteria.
Type:
Grant
Filed:
December 8, 2016
Date of Patent:
September 22, 2020
Assignee:
GlaxoSmithKline Intellectual Property Development Limited
Inventors:
Qi Jin, Denise Teotico Pohlhaus, Jared T. Spletstoser
Abstract: The present invention relates to compounds, compositions, combinations and medicaments containing said compounds and processes for their preparation. The invention also relates to the use of said compounds, combinations, compositions and medicaments, for example as inhibitors of the activity of RIP2 kinase, including degrading RIP2 kinase, the treatment of diseases and conditions mediated by the RIP2 kinase, in particular for the treatment of inflammatory diseases or conditions.
Type:
Grant
Filed:
April 18, 2017
Date of Patent:
September 22, 2020
Assignee:
GlaxoSmithKline Intellectual Property Development Limited
Inventors:
Linda N. Casillas, John David Harling, Afjal Hussain Miah, Mark David Rackham, Ian Edward David Smith
Abstract: The present disclosure provides concealed type expandable luggage. The concealed type expandable luggage comprises: a lower shell, an upper shell, and an expanded part, the expanded part including a first expanded portion and a second expanded portion, wherein one end of the first expanded portion is connected to the upper shell, one end of the second expanded portion is connected to the lower shell, and the other end of the first expanded portion is connectable to the other end of the second expanded portion to increase an accommodation space of the concealed type expandable luggage; and wherein the lower shell is directly connectable to the upper shell, such that the expanded part is accommodated and concealed in the accommodation space formed by fitting of the lower shell and the upper shell.
Abstract: Disclosed is a TLR4 agonist alone or in combination with an anti-cancer agent and pharmaceutical compositions thereof, uses thereof, and methods of treatment comprising administering said composition or combination, including uses in cancer.
Type:
Grant
Filed:
June 3, 2016
Date of Patent:
September 8, 2020
Assignee:
GlaxoSmithKline Intellectual Property Development Limited